



14 December 2020

Sydney, Australia

Appointment of New Auditor

Sydney, 14 December 2020: Nyrada Inc (ASX: NYR), in accordance with Listing Rule 3.16.3, announces that William Buck Audit (Vic) Pty Ltd has been appointed as auditor of the Company. The appointment follows the resignation of Nexia Sydney Audit Pty Ltd.

The change of auditor arose as a result of a tender process undertaken by the Company following the completion of the annual audit for the period ending 30 June 2020.

The Company wishes to thank Nexia and Mr Stephen Fisher (Director) for their services to the company over recent years.

About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular, neurological, and inflammatory/autoimmune diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited.

-ENDS-

Authorised by Mr John Moore, Non-Executive Chairman, on behalf of the Board.

www.nyrada.com

Investor & Corporate Enquiries:

Prue Kelly
T: 0459 022 445
E: info@nyrada.com

Company Secretary:

David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com